Alphyn Biologics, an Annapolis, Md.- and Cincinnati, Ohio-based clinical-stage dermatology company developing first-in-class multi-target therapeutics, closed a Series A financing round of approximately $3.3m.
The round was led by Queen City Angels, with participation from the Angel Physicians Fund and Serial Stage Venture Partners.
The company, which has raised approximately $6.7 million to date, including a seed round of more than $1 million, and a second round of more than $2 million, intends to use the funds to conduct the Phase2a clinical trial of AB-101a, its lead candidate for the treatment of mild-to-moderate atopic dermatitis (AD), the most common form of eczema.
Led by CEO Neal Koller, Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in a Phase 2a clinical trial.
AB-101a, a non-steroidal, targets common bacteria such as Staph and highly drug-resistant methicillin-resistant Staph (MRSA) that worsen AD and prevent its healing.
The company has a wholly owned subsidiary in Australia.
FinSMEs
19/09/2022